TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026PRNewsWire · 6 days ago
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal CancerGuruFocus · Oct 13, 2026
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal CancerBusiness Wire · Oct 13, 2026
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-UpPRNewsWire · Sep 28, 2026
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-OncologyPRNewsWire · Sep 22, 2026
TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer TranscriptSeeking Alpha · Sep 16, 2026TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | – | -$7.17 | |
| May 15, 2026 | – | -$21.28 | |
| Apr 15, 2026 | -$10.08 | -$18.58 | Miss |
| Nov 14, 2025 | -$9.24 | -$5.49 | Beat |
| Aug 14, 2025 | -$8.68 | -$4.94 | Beat |
| May 21, 2025 | -$2.00 | -$70.28 | Miss |